Following on from boom's post I think it was Lindy Durrant (or one of the scancell team as I remember) who made the point that if you can locate a site to inject it then you can reach it to cut it out. It is the inoperable sites or the unseen traces which scancell's products can clear out, which gives them a clear lead in effectiveness over oncosec.
Hey buddy . . . . . I don't remember a total figure re total II holdings, except perhaps the reuters website that was showing incorrect data. Then again - brain frazzle seems to be on the increase in my case . . . . . . memory on the fritz. O/T - bit of a showdown at the bridge tomorrow. ATB
There have been many previous discussions on this bb about OncoSec. If you google OncoSec and Puritas you should get some info. I know that both Wild, Crumbs and myself (and probably many others) have also posted in the past about the similarities and differences between the two, again you should be able to google these. I would just make a couple of points. Firstly, the last time I looked, OncoSec hadn't posted any survival data on any of its trials. This may have now changed. Secondly the Companies are aiming for a different markets. Scancell are intending for SCIB1 primarily to be a treatment for resected patients - OncoSec are unable to operate in this market. OncoSec's vaccine has to be injected directly into the lesion and therefore can't be used on resected patients .
Was it not your goodself who mentioned to me a couple of weeks back that the iis had 63% of Scancell. Milk that cow, likewise Inanaco has explained big differences between the two. I am sure he will write up a relevant post. You say...................... It is believed this will be the historical winner over Scancell, which I was concerned to hear. I am not very updated on OncoSec if someone could help me out it would be great. Could you kindly expand on who said that.
I'll save you some trouble .. " All 14 study patients produced a melanoma-specific T-cell response to treatment " I make that 100% ? Take care ..
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.